Eugenia supra-axillaris Essential Oil and Its Nanoemulsion: Chemical Characterization, In Vivo Anti-Inflammatory, Analgesic, and Antipyretic Activities

Table 3

Central analgesic efficiency of the ESA-EO and ESA-EO-NE.

Group	30 min.	60 min.	90 min.	120 min.
Negative control	6.68 ± 1.29 (--)	6.6 ± 0.089 (--)^dc	6.8 ± 0.84 (--)^dc	8.28 ± 0.67
Diclofenac (30 mg/kg)	11.4 ± 1.64 (70.79)	12.15 ± 0.25 (84.09)^a	11.65 ± 0.79 (71.32)^a	9.23 ± 1.58 (11.48)
Celecoxib (50 mg/kg)	11.05 ± 0.82 (65.54)	11.63 ± 0.83 (76.21)^a	12.08 ± 1.02 (77.65)^a	9.95 ± 0.88 (20.24)
ESA-EO (50 mg/kg)	10.4 ± 1.11 (55.81)	11.9 ± 1.38 (80.30)^a	10.08 ± 1.34 (48.24)	8.53 ± 1.29 (3.02)
ESA-EO (100 mg/kg)	11.78 ± 1.27 (76.48)	12.3 ± 0.60 (86.36)^a	13.65 ± 0.53 (100.74)^a	10.23 ± 0.60 (23.63)
ESA-EO-NE (50 mg/kg)	10.36 ± 1.29 (55.21)	11.83 ± 0.45 (79.24)^a	11.3 ± 0.91 (66.18)^a	10.63 ± 1.68 (28.46)
ESA-EO-NE (100 mg/kg)	13.32 ± 0.15 (99.55)^a	12.88 ± 0.13 (95.15)^a	13.68 ± 0.23 (101.18)^a	11.88 ± 1.84 (43.56)

Data are expressed as mean ± SE where n = 6. Statistics were carried out by one-way ANOVA and confirmed by Tukey’s multiple comparison tests. was assumed to denote statistical significance. ^aStatistically significant from the control negative group. ^cStatistically significant from the diclofenac group. ^dStatistically significant from the celecoxib group.